Start here
Current state
Where the disease stands in 2026 — burden, what the science has moved on, and where the delivery system has not.
Diagnosis
Plasma biomarkers, CSF, PET, APOE — the diagnostic toolkit and the workflow it actually fits into.
Treatment landscape
What is approved, what it does, and what defines real-world access to disease-modifying therapy.
Pipeline
Tau, GLP-1, neuroinflammation, synaptic resilience — the mechanisms in late-stage Alzheimer's development.
Patient journey
From first concern to long-term care — the decision points that shape what happens next for patients and families.